Yes, really. A groundbreaking 2018 study† proved that VASCEPA lowers your chance of a life-threatening heart attack or stroke by 25% when added to a statin*.
†REDUCE-IT® study N Engl J Med. 2019;380(1):11-22.
*In a clinical study, patients treated with VASCEPA had fewer cardiovascular events (17.2%) compared to those who took placebo (22%).
How much ground did this study actually break?
When medical societies saw the results, they immediately recognized the active ingredient in VASCEPA, icosapent ethyl, in their guidelines.
Why? Cardiovascular disease is an epidemic, and a 25% reduction in risk* on top of statins is a very significant breakthrough.
To be clear, statins are still recommended for high cholesterol, but even with a statin, significant cardiovascular risk can remain. We call this:
Protect your heart
with an additional
cardiovascular risk reduction* when you add VASCEPA to your statin.
If you cannot take statins, talk to your doctor about
whether or not VASCEPA can help you.
How we got here.
- Landmark REDUCE-IT® included over 8000 statin-treated patients with high triglycerides and lasted nearly 5 years
- In addition to taking a statin, most patients were also taking medication to manage conditions like high blood pressure and diabetes
- In this study, patients treated with VASCEPA had fewer cardiovascular events (17.2%) compared to those who took placebo (22%)
How VASCEPA reduces cardiovascular risk
VASCEPA is the first and only FDA-approved medication to lower CV risk in addition to other medications, such as statins, in patients with heart disease or diabetes and other risk factors. The clinical effects of VASCEPA are believed to include multiple factors. The exact science of how VASCEPA works in your body is not fully understood, but years of clinical testing have led to proven clinical results in lowering P-CVR with VASCEPA. Ask your doctor about heart protection with VASCEPA.